Here are four things to know.
1. Through the deal, Allergan will add Zeltiq’s CoolSculpting System to its portfolio of aesthetic products, which includes Botox.
2. The CoolSculpting System is intended to kill fat cells through a cooling mechanism.
3. In 2016, Zeltiq’s fat loss system generated $350 million in sales — paid directly by consumers as insurers do not cover the system, reports Reuters.
4. The deal is expected to close in the second half of 2017.
More articles on supply chain:
Marathon pauses launch of muscular dystrophy drug following price scrutiny: 6 things to know
Glassdoor ranks supply chain manager as 18th best job in US
A look into the supply chains of classic Valentine’s Day gifts
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.